SLC1A5 and neoplasm: Typically, V9302 was a well-known glutamine metabolism inhibitor, which could block glutamine uptake and metabolism of tumor cells by inhibiting the activity of alanine–serine–cysteine transporter 2 (ASCT2), a sodium-dependent solute carrier protein responsible for the primary transporter of glutamine in cancer cells [20–22].